| scholarly article | Q13442814 |
| P356 | DOI | 10.1359/JBMR.070711 |
| P698 | PubMed publication ID | 17638576 |
| P2093 | author name string | Patrick W Mantyh | |
| Ryan J Buus | |||
| Jack L Lewis | |||
| Michael A Kuskowski | |||
| Christopher M Peters | |||
| Joseph R Ghilardi | |||
| Katie T Freeman | |||
| Juan M Jimenez-Andrade | |||
| Nathan J Koewler | |||
| Lucy J Sullivan | |||
| Monica B Herrera | |||
| P2860 | cites work | An estimate of the worldwide prevalence and disability associated with osteoporotic fractures | Q36597363 |
| P433 | issue | 11 | |
| P921 | main subject | bone fracture | Q68833 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1732-1742 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur | |
| P478 | volume | 22 |
| Q61442952 | A C-terminal cysteine residue is required for peptide-based inhibition of the NGF/TrkA interaction at nM concentrations: implications for peptide-based analgesics |
| Q51529943 | A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. |
| Q33779598 | A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. |
| Q92153883 | Administration of Tramadol or Buprenorphine via the drinking water for post-operative analgesia in a mouse-osteotomy model |
| Q35064559 | Antagonism of nerve growth factor-TrkA signaling and the relief of pain |
| Q36796273 | Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis |
| Q89562296 | Anti-nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain |
| Q26746194 | Anti-nerve growth factor in pain management: current evidence |
| Q55318070 | Anti-nerve growth factor therapy attenuates cutaneous hypersensitivity and musculoskeletal discomfort in mice with osteoporosis. |
| Q38903010 | Anti-nerve growth factor therapy increases spontaneous day/night activity in mice with orthopedic surgery-induced pain |
| Q58112374 | Antinerve growth factor monoclonal antibodies for the control of pain in dogs and cats |
| Q37398720 | Capsaicin-sensitive sensory nerve fibers contribute to the generation and maintenance of skeletal fracture pain |
| Q33765435 | Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund's Adjuvant-induced knee arthritis |
| Q38040648 | Control of arthritis pain with anti-nerve-growth factor: risk and benefit |
| Q36558056 | Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists |
| Q87417860 | Early, middle, or late administration of zoledronate alleviates spontaneous nociceptive behavior and restores functional outcomes in a mouse model of CFA-induced arthritis |
| Q30430874 | Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats |
| Q22000853 | Expression and regulation of neurotrophins in the nondegenerate and degenerate human intervertebral disc |
| Q48602851 | Femur Window Chamber Model for In Vivo Cell Tracking in the Murine Bone Marrow |
| Q55264146 | First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain. |
| Q88523823 | GDNF, Neurturin, and Artemin Activate and Sensitize Bone Afferent Neurons and Contribute to Inflammatory Bone Pain |
| Q47111283 | Immunohistochemical localization of nerve growth factor, tropomyosin receptor kinase A, and p75 in the bone and articular cartilage of the mouse femur. |
| Q33880198 | Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis |
| Q33610520 | Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain. |
| Q57790366 | Mechanisms that drive bone pain across the lifespan |
| Q41684342 | Molecular Mechanisms That Contribute to Bone Marrow Pain |
| Q34617294 | NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use |
| Q92400214 | Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety |
| Q37604491 | Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model |
| Q38131207 | Nerve growth factor: an update on the science and therapy. |
| Q93076198 | Nerves in Bone: Evolving Concepts in Pain and Anabolism |
| Q89287365 | New Insights in Understanding and Treating Bone Fracture Pain |
| Q35701568 | New advances in musculoskeletal pain. |
| Q30657180 | Orthopedic surgery and bone fracture pain are both significantly attenuated by sustained blockade of nerve growth factor |
| Q36245918 | Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice |
| Q34486451 | Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers |
| Q50060345 | The Changing Sensory and Sympathetic Innervation of the Young, Adult and Aging Mouse Femur |
| Q97644214 | The Efficacy of Nerve Growth Factor Antibody for the Treatment of Osteoarthritis Pain and Chronic Low-Back Pain: A Meta-Analysis |
| Q26747520 | The Physiology of Bone Pain. How Much Do We Really Know? |
| Q34402192 | The neurobiology of skeletal pain |
| Q35676163 | The pathophysiology of acute pain: animal models |
| Q37418810 | Transient receptor potential vanilloid 1-immunoreactive innervation increases in fractured rat femur |
| Q37381681 | Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and anti-neurotrophic factor as a possible alternative |
| Q39331622 | Treatment of chronic low back pain - new approaches on the horizon |
| Q88739365 | [Local injection of exogenous nerve growth factor improves early bone maturation of implants] |
Search more.